ES
CMPX icon

Enavate Sciences’s Compass Therapeutics CMPX Stock Holding History

Enavate Sciences’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.2M Hold
7,788,150
– – 11.72% 4
2025
Q4 		$41.8M Hold
7,788,150
– – 8.25% 5
2025
Q3 		$27.3M Hold
7,788,150
– – 8.32% 6
2025
Q2 		$20.2M Hold
7,788,150
– – 11.47% 5
2025
Q1 		$14.8M Hold
7,788,150
– – 11.15% 6
2024
Q4 		$11.3M Buy
+7,788,150
New +$12.9M 8.11% 5

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Enavate Sciences's CMPX Position: Q1 2026 in Review

Enavate Sciences held its Compass Therapeutics (CMPX) position steady in Q1 2026 at 7,788,150 shares worth $41.2M. The position accounts for 11.72% of the portfolio, ranked #4.

Enavate Sciences first reported a position in CMPX in Q4 2024 and has held it in 6 quarters since. The position peaked at $41.8M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Enavate Sciences held 7,788,150 shares of Compass Therapeutics worth $41.2M as of Q1 2026.
  • Enavate Sciences left its Compass Therapeutics share count unchanged in Q1 2026.
  • Compass Therapeutics made up 11.72% of Enavate Sciences's portfolio in Q1 2026, its #4 holding.
  • Enavate Sciences first reported a position in Compass Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Enavate Sciences's Compass Therapeutics position peaked at $41.8M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Enavate Sciences's 13F filing for Q1 2026, filed 15 May 2026.